Despite limited clinical evidence, all available data suggest that intradermal administration of the Bavarian Nordic-produced Jynneos® vaccine will be as immunogenic as subcutaneous dosing for preventing monkeypox infection and illness, which leads us to favor intradermal use from both the individual and public health perspectives, wrote a group of vaccine experts.
'Vaccines work only if they are accessible, trusted, and used.'
Read More
